nodes	percent_of_prediction	percent_of_DWPC	metapath
Conivaptan—AVPR2—G alpha (s) signalling events—DRD5—attention deficit hyperactivity disorder	0.03	0.0325	CbGpPWpGaD
Conivaptan—AVPR1A—central nervous system—attention deficit hyperactivity disorder	0.0175	0.227	CbGeAlD
Conivaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.0172	0.0186	CbGpPWpGaD
Conivaptan—AVPR2—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.017	0.0185	CbGpPWpGaD
Conivaptan—AVPR2—G alpha (s) signalling events—DRD1—attention deficit hyperactivity disorder	0.0169	0.0183	CbGpPWpGaD
Conivaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.0168	0.0182	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.0167	0.0181	CbGpPWpGaD
Conivaptan—AVPR2—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.0167	0.0181	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.0166	0.018	CbGpPWpGaD
Conivaptan—AVPR2—nervous system—attention deficit hyperactivity disorder	0.015	0.196	CbGeAlD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.0147	0.0159	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.0146	0.0158	CbGpPWpGaD
Conivaptan—AVPR2—central nervous system—attention deficit hyperactivity disorder	0.0145	0.188	CbGeAlD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.0144	0.0156	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.0143	0.0155	CbGpPWpGaD
Conivaptan—AVPR1A—brain—attention deficit hyperactivity disorder	0.0139	0.181	CbGeAlD
Conivaptan—AVPR2—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.0122	0.0132	CbGpPWpGaD
Conivaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.0117	0.0126	CbGpPWpGaD
Conivaptan—AVPR2—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.0116	0.0126	CbGpPWpGaD
Conivaptan—AVPR2—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.0116	0.0125	CbGpPWpGaD
Conivaptan—AVPR2—brain—attention deficit hyperactivity disorder	0.0115	0.15	CbGeAlD
Conivaptan—AVPR1A—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.0112	0.0121	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.0111	0.012	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.011	0.0119	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.0109	0.0118	CbGpPWpGaD
Conivaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.0102	0.011	CbGpPWpGaD
Conivaptan—AVPR2—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.0101	0.011	CbGpPWpGaD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00999	0.0108	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00991	0.0107	CbGpPWpGaD
Conivaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00947	0.0103	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00943	0.0102	CbGpPWpGaD
Conivaptan—AVPR2—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.0094	0.0102	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00937	0.0101	CbGpPWpGaD
Conivaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00917	0.00994	CbGpPWpGaD
Conivaptan—AVPR2—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00911	0.00986	CbGpPWpGaD
Conivaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00902	0.00977	CbGpPWpGaD
Conivaptan—AVPR2—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00895	0.0097	CbGpPWpGaD
Conivaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.0089	0.00965	CbGpPWpGaD
Conivaptan—AVPR2—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00884	0.00958	CbGpPWpGaD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00873	0.00945	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00867	0.00939	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00857	0.00928	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00851	0.00921	CbGpPWpGaD
Conivaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.0083	0.00899	CbGpPWpGaD
Conivaptan—AVPR2—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00824	0.00892	CbGpPWpGaD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00811	0.00879	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00806	0.00873	CbGpPWpGaD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00786	0.00851	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.0078	0.00845	CbGpPWpGaD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00772	0.00837	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00767	0.00831	CbGpPWpGaD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00763	0.00826	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.0076	0.00824	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00757	0.0082	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00755	0.00818	CbGpPWpGaD
Conivaptan—AVPR1A—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.00752	0.00814	CbGpPWpGaD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00711	0.0077	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00706	0.00764	CbGpPWpGaD
Conivaptan—CYP3A4—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.00704	0.00762	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.00672	0.00728	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00665	0.0072	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.0066	0.00715	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00633	0.00685	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00628	0.00681	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.0062	0.00672	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00618	0.00669	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00615	0.00667	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00613	0.00665	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00598	0.00648	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00594	0.00644	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00588	0.00637	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00584	0.00633	CbGpPWpGaD
Conivaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00581	0.00629	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00581	0.00629	CbGpPWpGaD
Conivaptan—AVPR2—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00577	0.00625	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00577	0.00625	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00575	0.00622	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00571	0.00618	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00563	0.0061	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00559	0.00605	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00541	0.00586	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00537	0.00582	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00506	0.00548	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00502	0.00544	CbGpPWpGaD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00498	0.00539	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00494	0.00535	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.0043	0.00465	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00427	0.00462	CbGpPWpGaD
Conivaptan—AVPR2—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.00423	0.00458	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00395	0.00428	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00392	0.00425	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.0039	0.00423	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00387	0.0042	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.00379	0.00411	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.00376	0.00408	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00376	0.00407	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00373	0.00404	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00349	0.00378	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00347	0.00376	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.00341	0.00369	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00339	0.00368	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.00339	0.00367	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00338	0.00366	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00337	0.00365	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00336	0.00364	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00333	0.0036	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.00332	0.0036	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.0033	0.00358	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.0033	0.00358	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.00328	0.00356	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00326	0.00353	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.00326	0.00353	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00324	0.00351	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.00317	0.00343	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.00315	0.00341	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.00307	0.00333	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.00306	0.00331	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.00305	0.0033	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.00304	0.00329	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.00302	0.00327	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.003	0.00325	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.00298	0.00323	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.00296	0.00321	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.00278	0.00301	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.00276	0.00299	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.00231	0.0025	CbGpPWpGaD
Conivaptan—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.00229	0.0298	CbGeAlD
Conivaptan—AVPR2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.00229	0.00248	CbGpPWpGaD
Conivaptan—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.0022	0.0287	CbGeAlD
Conivaptan—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00216	0.00234	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.00214	0.00232	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.00213	0.0023	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.00201	0.00218	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.002	0.00217	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.00195	0.00211	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.00193	0.00209	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.00187	0.00203	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.00186	0.00201	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.00181	0.00197	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.0018	0.00195	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.00178	0.00193	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.00177	0.00192	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.00176	0.00191	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.00175	0.00189	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.00164	0.00178	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.00163	0.00176	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00116	0.00125	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.00115	0.00124	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00115	0.00124	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00114	0.00124	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.00114	0.00124	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000609	0.000659	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000604	0.000655	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000473	0.000512	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000327	0.000354	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000327	0.000354	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000321	0.000348	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000299	0.000323	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000261	0.000283	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000248	0.000269	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	0.000198	0.000214	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000196	0.000213	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	8.48e-05	9.19e-05	CbGpPWpGaD
